drugset / Trial / NCT00441545
Head to Head Study Against Sevelamer Hydrochloride
RandomizedCrossoverOpen-labelTreatment
Summary
To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.
Timeline
- Start
- 2007-01-05
- Primary completion
- 2008-07-31
- Completion
- 2008-07-31
Outcome
Missed primary endpoint
registry analysis (unspecified test); Fosrenol vs Sevelamer HCl; p = 0.1130; ANCOVA NCT00441545 ↗
Publications
- Background Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct;72(4):252-8. doi: 10.5414/cnp72252.
- Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanthanum Carbonate | Other / unclassified | 3000 mg | Oral |
| Comparator | Sevelamer | Other / unclassified | 6400 mg | Oral |